Experience With Low-Dose Valganciclovir Prophylaxis in Adult Liver Transplant Recipients

R. Dupuis, M. Harris, K. Gillis, D. Gerber, Jeffrey Fair, R. Watson, T. Koslowski, K. Andreoni

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Valganciclovir (VGCV) is considered the agent of choice after organ transplant for cytomegalovirus (CMV) prophylaxis. The purpose of this retrospective study was to determine the effectiveness and safety of a low-dose regimen after liver transplant (OLT). Eighty-five patients who underwent OLT between August 2002 and August 2004 were included. All patient data for the first 12 months after transplant were collected. Patients received VGCV 450 mg once daily for 3 months posttransplant. CMV infection was based on detection of CMV virus or viral proteins in blood. CMV disease was defined by the presence of positive antigenemia/viremia and evidence of clinical symptoms and/or tissue findings. Patients were D+R+ (54%) and D-R+ (29%), D+R-(11%) and D-R-(6%). Overall, CMV infection and disease occurred in 13% (11/85). CMV infection and disease occurred in 7% and 6%, respectively. CMV infection and disease occurred in 44% (D+R-), 13% (D+R+), 4% (D-R+) patients. The mean time to onset of CMV infection and disease was 103 days (14 to 312 days). Overall, 82% of patients received antibody therapy. The most common adverse events associated with VGCV were leukopenia (16%), thrombocytopenia (4%), anemia (

Original languageEnglish (US)
Pages (from-to)3266-3270
Number of pages5
JournalTransplantation Proceedings
Volume39
Issue number10
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Cytomegalovirus Infections
Liver
Cytomegalovirus
Transplants
Viremia
Leukopenia
Viral Proteins
Transplant Recipients
valganciclovir
Anemia
Retrospective Studies
Viruses
Safety
Antibodies

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Experience With Low-Dose Valganciclovir Prophylaxis in Adult Liver Transplant Recipients. / Dupuis, R.; Harris, M.; Gillis, K.; Gerber, D.; Fair, Jeffrey; Watson, R.; Koslowski, T.; Andreoni, K.

In: Transplantation Proceedings, Vol. 39, No. 10, 12.2007, p. 3266-3270.

Research output: Contribution to journalArticle

Dupuis, R, Harris, M, Gillis, K, Gerber, D, Fair, J, Watson, R, Koslowski, T & Andreoni, K 2007, 'Experience With Low-Dose Valganciclovir Prophylaxis in Adult Liver Transplant Recipients', Transplantation Proceedings, vol. 39, no. 10, pp. 3266-3270. https://doi.org/10.1016/j.transproceed.2007.09.037
Dupuis, R. ; Harris, M. ; Gillis, K. ; Gerber, D. ; Fair, Jeffrey ; Watson, R. ; Koslowski, T. ; Andreoni, K. / Experience With Low-Dose Valganciclovir Prophylaxis in Adult Liver Transplant Recipients. In: Transplantation Proceedings. 2007 ; Vol. 39, No. 10. pp. 3266-3270.
@article{57d72a3efdae4e7a89ef1ac278dd9d6c,
title = "Experience With Low-Dose Valganciclovir Prophylaxis in Adult Liver Transplant Recipients",
abstract = "Valganciclovir (VGCV) is considered the agent of choice after organ transplant for cytomegalovirus (CMV) prophylaxis. The purpose of this retrospective study was to determine the effectiveness and safety of a low-dose regimen after liver transplant (OLT). Eighty-five patients who underwent OLT between August 2002 and August 2004 were included. All patient data for the first 12 months after transplant were collected. Patients received VGCV 450 mg once daily for 3 months posttransplant. CMV infection was based on detection of CMV virus or viral proteins in blood. CMV disease was defined by the presence of positive antigenemia/viremia and evidence of clinical symptoms and/or tissue findings. Patients were D+R+ (54{\%}) and D-R+ (29{\%}), D+R-(11{\%}) and D-R-(6{\%}). Overall, CMV infection and disease occurred in 13{\%} (11/85). CMV infection and disease occurred in 7{\%} and 6{\%}, respectively. CMV infection and disease occurred in 44{\%} (D+R-), 13{\%} (D+R+), 4{\%} (D-R+) patients. The mean time to onset of CMV infection and disease was 103 days (14 to 312 days). Overall, 82{\%} of patients received antibody therapy. The most common adverse events associated with VGCV were leukopenia (16{\%}), thrombocytopenia (4{\%}), anemia (",
author = "R. Dupuis and M. Harris and K. Gillis and D. Gerber and Jeffrey Fair and R. Watson and T. Koslowski and K. Andreoni",
year = "2007",
month = "12",
doi = "10.1016/j.transproceed.2007.09.037",
language = "English (US)",
volume = "39",
pages = "3266--3270",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Experience With Low-Dose Valganciclovir Prophylaxis in Adult Liver Transplant Recipients

AU - Dupuis, R.

AU - Harris, M.

AU - Gillis, K.

AU - Gerber, D.

AU - Fair, Jeffrey

AU - Watson, R.

AU - Koslowski, T.

AU - Andreoni, K.

PY - 2007/12

Y1 - 2007/12

N2 - Valganciclovir (VGCV) is considered the agent of choice after organ transplant for cytomegalovirus (CMV) prophylaxis. The purpose of this retrospective study was to determine the effectiveness and safety of a low-dose regimen after liver transplant (OLT). Eighty-five patients who underwent OLT between August 2002 and August 2004 were included. All patient data for the first 12 months after transplant were collected. Patients received VGCV 450 mg once daily for 3 months posttransplant. CMV infection was based on detection of CMV virus or viral proteins in blood. CMV disease was defined by the presence of positive antigenemia/viremia and evidence of clinical symptoms and/or tissue findings. Patients were D+R+ (54%) and D-R+ (29%), D+R-(11%) and D-R-(6%). Overall, CMV infection and disease occurred in 13% (11/85). CMV infection and disease occurred in 7% and 6%, respectively. CMV infection and disease occurred in 44% (D+R-), 13% (D+R+), 4% (D-R+) patients. The mean time to onset of CMV infection and disease was 103 days (14 to 312 days). Overall, 82% of patients received antibody therapy. The most common adverse events associated with VGCV were leukopenia (16%), thrombocytopenia (4%), anemia (

AB - Valganciclovir (VGCV) is considered the agent of choice after organ transplant for cytomegalovirus (CMV) prophylaxis. The purpose of this retrospective study was to determine the effectiveness and safety of a low-dose regimen after liver transplant (OLT). Eighty-five patients who underwent OLT between August 2002 and August 2004 were included. All patient data for the first 12 months after transplant were collected. Patients received VGCV 450 mg once daily for 3 months posttransplant. CMV infection was based on detection of CMV virus or viral proteins in blood. CMV disease was defined by the presence of positive antigenemia/viremia and evidence of clinical symptoms and/or tissue findings. Patients were D+R+ (54%) and D-R+ (29%), D+R-(11%) and D-R-(6%). Overall, CMV infection and disease occurred in 13% (11/85). CMV infection and disease occurred in 7% and 6%, respectively. CMV infection and disease occurred in 44% (D+R-), 13% (D+R+), 4% (D-R+) patients. The mean time to onset of CMV infection and disease was 103 days (14 to 312 days). Overall, 82% of patients received antibody therapy. The most common adverse events associated with VGCV were leukopenia (16%), thrombocytopenia (4%), anemia (

UR - http://www.scopus.com/inward/record.url?scp=37049017978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37049017978&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2007.09.037

DO - 10.1016/j.transproceed.2007.09.037

M3 - Article

VL - 39

SP - 3266

EP - 3270

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -